ORMC
  • Orange Regional Health Connection

    1-888-321-6762

  • Text Size:

  • Print:

    Print
  • Share:

    Share

**TRAVEL ADVISORY**
**FLU ADVISORY**
**AVISO**



Clinical Trials

Lung Protocols

Please check with your physician for additional protocols and/or information.

 

1.  E5508:  A Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed or Both Following Carboplatin, Paclitxel & Bevacizumab for Advanced Non-Squamous Cell Lung Cancer

The purpose of this study is to find out the best maintenance therapy for patients with advanced stage non-small cell lung cancer. Maintenance therapy is usually given after 4 cycles of standard chemotherapy (1 cycle = 21 days) to keep the disease under control for a longer duration. This study will compare the effects, good and/or bad, of bevacizumab, pemetrexed or the combination of the two agents when given as maintenance therapy.

2.  S1300:  A Randomized Phase II Trial of Crizotinib +Pemetrexed vs. Pemetrexed Monotherapy in ALK Positive Non-Squamous NSCLC Patients who Have Progressed Systemically After Previous Clinical Benefit from Crizotinib Monotherapy

The purpose of this study is to compare any good and bad effects of reintroducing crizotinib along with the drug pemetrexed to pemetrexed alone.  The addition of crizotinib to pemetrexed will likely increase the side effects of treatment, but it is possible that the combination could either shrink your tumor or prevent it from coming back more effectively than pemetrexed alone.  This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.  Crizotinib is already FDA-approved for use in advanced ALK-positive cancer but is usually not given again after the cancer progresses.

3.  CALGB 30901:  A Randomized Phase II Study of Maintenance Pemetrexed vs. Observation for Patients with Malignant Pleural Mesothelioma without Progression After First Line Chemotherapy

The main purpose of this study is to find out whether continuation of chemotherapy with pemetrexed will increase the time before the mesothelioma begins to grow again. Pemetrexed is approved by the FDA to treat mesothelioma, but exactly how long to continue pemetrexed is not known.

For more information on these protocols or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133.  

Orange Regional Medical Center
707 East Main Street
Middletown, NY 10940
845-333-1000

Directions »

Orange Regional Medical Pavilion
75 Crystal Run Road
Middletown, NY 10940
845-695-5800

Directions »
Join Our Email List
For Medical Staff
For Employees
Disclaimer | Privacy Policy | Sitemap | Locations

Copyright © 2015 Orange Regional Medical Center
Joint Commission National Quality Approved
A member of the Greater Hudson Valley Health System